WO2021000969A3 - 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 - Google Patents

表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 Download PDF

Info

Publication number
WO2021000969A3
WO2021000969A3 PCT/CN2020/110086 CN2020110086W WO2021000969A3 WO 2021000969 A3 WO2021000969 A3 WO 2021000969A3 CN 2020110086 W CN2020110086 W CN 2020110086W WO 2021000969 A3 WO2021000969 A3 WO 2021000969A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
cov
antigen peptide
virus antigen
acid sequence
Prior art date
Application number
PCT/CN2020/110086
Other languages
English (en)
French (fr)
Other versions
WO2021000969A2 (zh
Inventor
陈凌
关素华
杨臣臣
刘晓琳
Original Assignee
广州恩宝生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010110070.8A external-priority patent/CN110951756B/zh
Priority claimed from CN202010145657.2A external-priority patent/CN110974950B/zh
Application filed by 广州恩宝生物医药科技有限公司 filed Critical 广州恩宝生物医药科技有限公司
Priority to EP20829298.7A priority Critical patent/EP3805392A4/en
Priority to US17/260,160 priority patent/US20220347289A1/en
Priority to PH12021550030A priority patent/PH12021550030A1/en
Publication of WO2021000969A2 publication Critical patent/WO2021000969A2/zh
Publication of WO2021000969A3 publication Critical patent/WO2021000969A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

提供了一种表达SARS-CoV-2病毒抗原肽的核酸及其应用，该核酸的序列为SEQIDNO:1或2所示的序列或与其具有至少90%同源性的序列。该核酸可在人体细胞中有效表达，产生相应的多肽，诱导产生相应的免疫保护反应。
PCT/CN2020/110086 2020-02-23 2020-08-19 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 WO2021000969A2 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20829298.7A EP3805392A4 (en) 2020-02-23 2020-08-19 Nucleic acid sequence expressing sars-cov-2 virus antigen peptide and use thereof
US17/260,160 US20220347289A1 (en) 2020-02-23 2020-08-19 Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
PH12021550030A PH12021550030A1 (en) 2020-02-23 2021-01-04 Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010110070.8A CN110951756B (zh) 2020-02-23 2020-02-23 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN202010110070.8 2020-02-23
CN202010145657.2A CN110974950B (zh) 2020-03-05 2020-03-05 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN202010145657.2 2020-03-05

Publications (2)

Publication Number Publication Date
WO2021000969A2 WO2021000969A2 (zh) 2021-01-07
WO2021000969A3 true WO2021000969A3 (zh) 2021-02-18

Family

ID=74100237

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2020/110086 WO2021000969A2 (zh) 2020-02-23 2020-08-19 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
PCT/CN2020/110085 WO2021000968A2 (zh) 2020-02-23 2020-08-19 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/110085 WO2021000968A2 (zh) 2020-02-23 2020-08-19 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Country Status (4)

Country Link
US (2) US20210283244A1 (zh)
EP (2) EP3804751A4 (zh)
PH (2) PH12021550030A1 (zh)
WO (2) WO2021000969A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
EP3922263A4 (en) * 2020-03-16 2022-06-29 Guangzhou N Biomed Ltd. Ad7 vector vaccine for preventing sars-cov-2 infection
BR112022019781A2 (pt) 2020-04-22 2022-12-13 BioNTech SE Vacina para o coronavírus
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN112679605B (zh) * 2021-03-15 2021-07-09 安源医药科技（上海）有限公司 针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
WO2023002492A1 (en) * 2021-07-22 2023-01-26 Yeda Research And Development Co. Ltd. Codon optimization of nucleic acids
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1570115A (zh) * 2003-07-16 2005-01-26 陈克勤 优化的sars冠状病毒刺突蛋白基因
WO2005047459A2 (en) * 2003-08-04 2005-05-26 University Of Massachusetts Sars nucleic acids, proteins, antibodies, and uses thereof
CN110951756A (zh) * 2020-02-23 2020-04-03 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950A (zh) * 2020-03-05 2020-04-10 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091524A2 (en) * 2003-04-14 2004-10-28 Acambis Inc. Respiratory virus vaccines
CN1276777C (zh) * 2003-05-21 2006-09-27 中山大学肿瘤防治中心 腺病毒载体sars疫苗及其制备方法，冠状病毒s基因的应用
CN100588708C (zh) * 2003-06-17 2010-02-10 深圳市源兴生物医药科技有限公司 抗sars疫苗
PL2163260T3 (pl) * 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
US20080267992A1 (en) * 2004-06-04 2008-10-30 Cancer Center, Sun Yat-Sun University Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
CN105273067A (zh) * 2015-03-13 2016-01-27 中国疾病预防控制中心病毒病预防控制所 一种编码MERS-CoV棘突蛋白的重组41型腺病毒载体疫苗
CN111821433B (zh) * 2020-02-06 2021-06-08 深圳市瑞吉生物科技有限公司 mRNA疫苗及其合成方法、试剂盒

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1570115A (zh) * 2003-07-16 2005-01-26 陈克勤 优化的sars冠状病毒刺突蛋白基因
WO2005047459A2 (en) * 2003-08-04 2005-05-26 University Of Massachusetts Sars nucleic acids, proteins, antibodies, and uses thereof
CN110951756A (zh) * 2020-02-23 2020-04-03 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950A (zh) * 2020-03-05 2020-04-10 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NUCLEOTIDE GENBANK; 18 July 2020 (2020-07-18), ANONYMOUS A: "Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome", XP055780561, Database accession no. NC_045512 *
LU, JIAN ET AL.: "Construction and Induction of Antibody Response by Recombinant DNA Containing SARS Coronavirus Full-Length or Truncated S Gene", CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, vol. 25, no. 11, 30 November 2005 (2005-11-30), pages 934 - 939, XP055781034, ISSN: 0254-5101 *
ZAKHARTCHOUK ALEXANDER N., VISWANATHAN SATHIYANARAYANAN, MOSHYNSKYY IGOR, PETRIC MARTIN, BABIUK LORNE A.: "Optimization of a DNA Vaccine Against SARS", DNA AND CELL BIOLOGY, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 26, no. 10, 1 October 2007 (2007-10-01), US, pages 721 - 726, XP055780557, ISSN: 1044-5498, DOI: 10.1089/dna.2007.0616 *

Also Published As

Publication number Publication date
US20210283244A1 (en) 2021-09-16
US20220347289A1 (en) 2022-11-03
EP3804751A2 (en) 2021-04-14
PH12021550029A1 (en) 2021-09-27
EP3805392A4 (en) 2022-06-29
WO2021000968A2 (zh) 2021-01-07
WO2021000969A2 (zh) 2021-01-07
PH12021550030A1 (en) 2021-09-20
EP3804751A4 (en) 2022-04-27
WO2021000968A3 (zh) 2021-02-18
EP3805392A2 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
WO2021000969A3 (zh) 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
NZ595501A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
IL86480A (en) Recombinant dna coding for human proapolipoprotein a-1,expression vectors containing it and cells transformed by said expression vector
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
NZ600690A (en) Fkbp-l and uses thereof
NZ603016A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
ATE519842T1 (de) Trichoderma reesei-glucoamylase und homologe davon
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
EP4276463A3 (en) Peptides
NZ534259A (en) A protein with homology to cysteine-rich secretory protein (CRISP) inhibitor
ATE452969T1 (de) Lipoxygenase-varianten und ihre verwendung
AP1502A (en) Genes and proteins, and their uses.
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
WO2020092769A3 (en) Silk nucleotides and proteins and methods of use
DE69634137D1 (de) Protein mit pflanzenschützenden eigenschaften
CN101659959B (zh) 一种人重组角蛋白19抗原活性片段表达载体及其应用
SG170092A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
WO2008029138A3 (en) Peptides and methods
DE60033823D1 (de) Rekombinante mikroorganismen
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
TR199802168T2 (xx) IL-16 Aktivitesine sahip işlenmiş polipeptidler, bunları üretmeye mahsus yöntemler ve bunların kullanımı.
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
NZ603105A (en) Detection of mutations in a gene associated with resistance to viral infection, oasi

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020829298

Country of ref document: EP

Effective date: 20210111

WWE Wipo information: entry into national phase

Ref document number: 2101000979

Country of ref document: TH

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20829298

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE